Health-related quality of life of patients with newly diagnosed chronic myeloid leukemia treated with allogeneic hematopoietic SCT versus imatinib

Bone Marrow Transplantation

Volumn 49, Issue 4, 2014, Pages 576-580

  Mo, X D ^a   Jiang, Q ^a   Xu, L P ^a   Liu, D H ^a   Liu, K Y ^a   Jiang, B ^a   Jiang, H ^a   Chen, H ^a   Chen, Y H ^a   Zhang, X H ^a   Han, W ^a   Wang, Y ^a   Huang, X J ^a  

^a PEKING UNIVERSITY PEOPLE S HOSPITAL   (China)

Author keywords

Allogeneic; Health related quality of life; Hematopoietic SCT; Identical sibling donor; Imatinib

Indexed keywords

IMATINIB; ANTINEOPLASTIC AGENT; BENZAMIDE DERIVATIVE; PIPERAZINE DERIVATIVE; PYRIMIDINE DERIVATIVE;

ADULT; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; CANCER SURVIVOR; CHRONIC MYELOID LEUKEMIA; CLINICAL TRIAL; COHORT ANALYSIS; COMPARATIVE EFFECTIVENESS; CROSS-SECTIONAL STUDY; FEMALE; HLA MATCHING; HUMAN; LETTER; LEUKOCYTE COUNT; LIVING DONOR; MAJOR CLINICAL STUDY; MALE; MENTAL HEALTH; PHYSICAL ACTIVITY; POPULATION RESEARCH; PRIORITY JOURNAL; PROSPECTIVE STUDY; QUALITY OF LIFE; SHORT FORM 36; SIBLING; THROMBOCYTE COUNT; ALLOTRANSPLANTATION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; PROCEDURES; PSYCHOLOGY; RISK FACTOR;

ADULT; ANTINEOPLASTIC AGENTS; BENZAMIDES; COHORT STUDIES; CROSS-SECTIONAL STUDIES; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; MALE; PIPERAZINES; PROSPECTIVE STUDIES; PYRIMIDINES; QUALITY OF LIFE; RISK FACTORS; TRANSPLANTATION, HOMOLOGOUS;

EID: 84897534782     PISSN: 02683369     EISSN: 14765365     Source Type: Journal    
DOI: 10.1038/bmt.2013.232     Document Type: Letter

References (36)

1. O'Brien S, Berman E, Moore JO, Pinilla-Ibarz J, Radich JP, Shami PJ et al. NCCN Task Force report: tyrosine kinase inhibitor therapy selection in the management of patients with chronic myelogenous leukemia. J Natl Compr Canc Netw 2011; 9: S1-S25.
2. Goldman JM. Initial treatment for patients with CML. Hematology Am Soc Hematol Educ Program 2009; 2009: 453-460.
3. Goldman JM. Treatment strategies for CML. Best Pract Res Clin Haematol 2009; 22: 303-313.
4. Pavlu J, Szydlo RM, Goldman JM, Apperley JF. Three decades of transplantation for chronic myeloid leukemia: what have we learned? Blood 2011; 117: 755-763.
5. Oyekunle A, Klyuchnikov E, Ocheni S, Kröger N, Zander AR, Baccarani M et al. Challenges for allogeneic hematopoietic stem cell transplantation in chronic myeloid leukemia in the era of tyrosine kinase inhibitors. Acta Haematol 2011; 126: 30-39.
6. Gratwohl A, Brand R, Apperley J, Crawley C, Ruutu T, Corradini P et al. Allogeneic hematopoietic stem cell transplantation for chronic myeloid leukemia in Europe 2006: transplant activity, long-term data and current results. An analysis by the Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT). Haematologica 2006 91: 513-521.
7. Giralt SA, Arora M, Goldman JM, Lee SJ, Maziarz RT, McCarthy PL et al. Impact of imatinib therapy on the use of allogeneic haematopoietic progenitor cell transplantation for the treatment of chronic myeloid leukaemia. Br J Haematol 2007; 137: 461-467.
8. Pasquini MC. Hematopoietic cell transplantation for chronic myeloid leukemia in developing countries: perspectives from Latin America in the post-tyrosine kinase inhibitor era. Hematology 2012; 17: S79-S82.
9. Gugliotta G, Castagnetti F, Palandri F, Breccia M, Intermesoli T, Capucci A et al. Frontline imatinib treatment of chronic myeloid leukemia: no impact of age on outcome, a survey by the GIMEMA CML Working Party. Blood 2011; 117: 5591-5599.
10. Goldman JM. How I treat chronic myeloid leukemia in the imatinib era. Blood 2007; 110: 2828-2837.
11. Bumbea H, Vladareanu AM, Voican I, Cisleanu D, Barsan L, Onisai M. Chronic myeloid leukemia therapy in the era of tyrosine kinase inhibitors - the first molecular targeted treatment. J Med Life 2010; 3: 162-166.
12. Hahn EA, Glendenning GA, Sorensen MV, Hudgens SA, Druker BJ, Guilhot F et al. Quality of life in patients with newly diagnosed chronic phase chronic myeloid leukemia on imatinib versus interferon alfa plus low-dose cytarabine: results from the IRIS Study. J Clin Oncol 2003; 21: 2138-2146.
13. Aziz Z, Iqbal J, Aaqib M, Akram M, Saeed A. Assessment of quality of life with imatinib mesylate as first-line treatment in chronic phase-chronic myeloid leukemia. Leuk Lymphoma 2011; 52: 1017-1023.
14. Efficace F, Baccarani M, Breccia M, Alimena G, Rosti G, Cottone F et al. Healthrelated quality of life in chronic myeloid leukemia patients receiving long-term therapy with imatinib compared with the general population. Blood 2011; 118: 4554-4560.
15. Chang G, Orav EJ, McNamara TK, Tong MY, Antin JH. Psychosocial function after hematopoietic stem cell transplantation. Psychosomatics 2005; 46: 34-40.
16. Kiss TL, Abdolell M, Jamal N, Minden MD, Lipton JH, Messner HA. Long-term medical outcomes and quality-of-life assessment of patients with chronic myeloid leukemia followed at least 10 years after allogeneic bone marrow transplantation. J Clin Oncol 2002; 20: 2334-2343.
17. Jiang Q, Xu LP, Liu DH, Liu KY, Gale RP, Zhang MJ et al. Imatinib results in better outcomes than HLA-identical sibling transplants in young persons with newly diagnosed chronic-phase chronic myelogenous leukemia. Leukemia 2013; 27: 2410-2413.
18. Ware JE, Kosinski M, Bayliss MS, McHorney CA, Rogers WH, Raczek A. Comparison of methods for the scoring and statistical analysis of SF-36 health profile and summary measures: summary of results from the Medical Outcomes Study. Med Care 1995; 33: AS264-AS279.
19. Li L, Wang HM, Shen Y. Chinese SF-36 Health Survey: translation, cultural adaptation, validation, and normalisation. J Epidemiol Community Health 2003; 57: 259-263.
20. Chen Z, Wang C, Xu X, Feng W. Cost-effectiveness study comparing imatinib with interferon-alpha for patients with newly diagnosed chronic-phase (CP) chronic myeloid leukemia (CML) from the Chinese public health-care system perspective (CPHSP). Value Health 2009; 12: S85-S88.
21. Liang Y, Lai Y, Schwarzenberger P, Li Q, Ma J, Luo J et al. Targeted agents for chronic myelogenous leukemia: will that be the end of allogeneic bone marrowtransplantation for that disease? Biol Blood Marrow Transplant 2010; 16: 848-853.
22. Sutherland HJ, Fyles GM, Adams G, Hao Y, Lipton JH. Quality of life following bone marrow transplantation: a comparison of patient reports with population norms. Bone Marrow Transplant 1997; 19: 1129-1136.
23. Duell T, van Lint MT, Ljungman P, Tichelli A, Socié G, Apperley JF et al. Health and functional status of long-term survivors of bone marrow transplantation. EBMT Working Party on Late Effects and EULEP Study Group on Late Effects. European Group for Blood and Marrow Transplantation. Ann Intern Med 1997; 126: 184-192.
24. Bush NE, Donaldson GW, Haberman MH, Dacanay R, Sullivan KM. Conditional and unconditional estimation of multidimensional quality of life after hematopoietic stem cell transplantation: a longitudinal follow-up of 415 patients. Biol Blood Marrow Transplant 2000; 6: 576-591.
25. Chiodi S, Spinelli S, Ravera G, Petti AR, Van Lint MT, Lamparelli T et al. Quality of life in 244 recipients of allogeneic bone marrow transplantation. Br J Haematol 2000; 110: 614-619.
26. Bevans MF, Marden S, Leidy NK, Soeken K, Cusack G, Rivera P et al. Health-related quality of life in patients receiving reduced-intensity conditioning allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplant 2006; 38: 101-109.
27. Millot F, Baruchel A, Guilhot J, Petit A, Leblanc T, Bertrand Y et al. Imatinib is effective in children with previously untreated chronic myelogenous leukemia in early chronic phase: results of the French national phase IV trial. J Clin Oncol 2011; 29: 2827-2832.
28. Lakshmaiah K, Bhise R, Purohit S, Abraham LJ, Lokanatha D, Suresh TM et al. Chronic myeloid leukemia in children and adolescents: Results of treatment with imatinib mesylate. Leuk Lymphoma 2012; 53: 2430-2433.
29. Kerkelä R, Grazette L, Yacobi R, Iliescu C, Patten R, Beahm C et al. Cardiotoxicity of the cancer therapeutic agent imatinib mesylate. Nat Med 2006; 12: 908-916.
30. Bansal D, Shava U, Varma N, Trehan A, Marwaha RK. Imatinib has adverse effect on growth in children with chronic myeloid leukemia. Pediatr Blood Cancer 2012; 59: 481-484.
31. Andolina JR, Neudorf SM, Corey SJ. How I treat childhood CML. Blood 2012; 119: 1821-1830.
32. Suttorp M, Yaniv I, Schultz KR. Controversies in the treatment of CML in children and adolescents: TKIs versus BMT? Biol Blood Marrow Transplant 2011; 17: S115-S122.
33. Weisser M, Ledderose G, Jochem Kolb H. Long-term follow-up of allogeneic HSCT for CML reveals significant improvement in the outcome over the last decade. Ann Hematol 2007; 86: 127-132.
34. Sokal JE, Cox EB, Baccarani M, Tura S, Gomez GA, Robertson JE et al. Prognostic discrimination in 'good-risk' chronic granulocytic leukemia. Blood 1984; 63: 789-799.
35. Hasford J, Pfirrmann M, Hehlmann R, Allan NC, Baccarani M, Kluin-Nelemans JC et al. A new prognostic score for survival of patients with chronic myeloid leukemia treated with interferon alfa. Writing Committee for the Collaborative CML Prognostic Factors Project Group. J Natl Cancer Inst 1998; 90: 850-858.
36. Mo XD, Xu LP, Liu DH, Chen YH, Han W, Zhang XH et al. Patients receiving HLAhaploidentical/partially matched related allo-HSCT can achieve desirable healthrelated QoL that is comparable to that of patients receiving HLA-identical sibling allo-HSCT. Bone Marrow Transplant 2012; 47: 1201-1205.